Clinical trials: Neuroendocrine; Carcinoma
Pancreatic Cancer, Pancreas Cancer
Role of Proton Pump Inhibitors on the Postoperative Course Following Pancreaticoduodenectomy
The purpose of this study is to prospectively determine the effects of administering proton pump inhibitors (PPIs) following pancreaticoduodenectomy on postoperative outcomes.
- Conditions
- Pancreatic Cancer, Pancreas Cancer, Ampullary Cancer, Pancreas Neuroendocrine Tumor
- Trial name
- NCT05251233
- Testing
- Pantoprazole
- Where
- United States
- Volunteers
- 56 people
- Sponsor
- Washington University School of Medicine
Neuroendocrine Tumors
Evaluation of [18F]Fluoroethyl Triazole Labelled [Tyr3]-Octreotate Analogues for the Imaging of Neuroendocrine Tumours.
Radiolabelled somatostatin analogs are invaluable in the diagnosis and treatment of neuroendocrine tumours (NET). The most common positron emission tomography (PET) radiotracers used for the visualisation of NET are radiolabelled…
- Trial name
- FETONET (NCT06456723)
- Testing
- [18F]-FET-βAG-TOCA
- Volunteers
- 56 people
- Sponsor
- Imperial College London
Carcinoma, Non-Small -Cell Lung, Ovarian Neoplasms
Trial of Topotecan With VX-970 (M6620), an ATR Kinase Inhibitor, in Small Cell Cancers and Extrapulmonary Small Cell Cancers
Background: Chemotherapy damages cancer cell deoxyribonucleic acid (DNA) so the cells die, and the tumor shrinks. But it may stop working in some people over time.
- Conditions
- Carcinoma, Non-Small -Cell Lung, Ovarian Neoplasms, Small Cell Lung Carcinoma, Uterine Cervical Neoplasms
- Trial name
- NCT02487095
- Testing
- Topotecan, VX-970 (M6620)
- Where
- United States
- Volunteers
- 62 people
- Sponsor
- National Cancer Institute (NCI)
Carcinoid Syndrome, Metastatic Nonfunctional Well Differentiated Neuroendocrine Neoplasm
AMT-PET in Monitoring Telotristat Etiprate Treatment in Participants With MetastaticNeuroendocrine Neoplasm
This pilot trial studies how well telotristat etiprate works in treating participants with well differentiated neuroendocrine neoplasm that has spread to other places in the body and monitored by carbon C 11…
- Trial name
- NCT03453489
- Testing
- Carbon C 11 Alpha-methyltryptophan, Laboratory Biomarker Analysis, Positron Emission Tomography
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Barbara Ann Karmanos Cancer Institute
Gastroenteropancreatic Neuroendocrine Tumor
Nutrition in Gastroenteropancreatic Neuroendocrine Tumor
It is well known that the prevalence of malnutrition or risk of malnutrition in cancer patients is high, as well as its impact on different parameters such as hospitalization, survival or response to certain treatments.
- Trial name
- NUTRIGETNE (NCT04986085)
- Where
- 16 sites in Spain
- Volunteers
- 399 people
- Sponsor
- Grupo Espanol de Tumores Neuroendocrinos
Small Cell Carcinoma, Carcinoma, Non-Small-Cell Lung
RRx-001 in Lung Cancer, Ovarian Cancer and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT)
This study is designed to explore the potential of the epigenetic agent RRx-001 to sensitize patients who previously received and now have failed a platinum based doublet regimen.
- Conditions
- Small Cell Carcinoma, Carcinoma, Non-Small-Cell Lung, Neuroendocrine Tumors, Ovarian Epithelial Cancer
- Trial name
- NCT02489903
- Testing
- RRx-001, Cisplatin, Etoposide
- Where
- 10 sites in United States
- Volunteers
- 139 people
- Sponsor
- EpicentRx, Inc.
Advanced Solid Tumor, Metastatic Solid Tumor
Lurbinectedin Monotherapy in Participants With Advanced or Metastatic Solid Tumors
This is an open-label, multicenter, phase 2 study of lurbinectedin monotherapy in participants with advanced (metastatic and/or unresectable) solid tumors.
- Conditions
- Advanced Solid Tumor, Metastatic Solid Tumor, Urothelial Cancer, Poorly Differentiated Neuroendocrine Carcinomas
- Trial name
- JAZZ EMERGE201 (NCT05126433)
- Testing
- Lurbinectedin
- Where
- 17 sites in United States
- Volunteers
- 47 people
- Sponsor
- Jazz Pharmaceuticals
Pancreatic Neuroendocrine Tumors
Phase IV Study of the Safety and Efficacy of Everolimus in Adult Patients With Progressive pNET in China
To evaluate safety and efficacy of everolimus (Afinitor®) in Chinese adult patients with local advanced or metastatic, well differentiated progressive pancreatic neuroendocrine tumors.
- Trial name
- NCT02842749
- Testing
- everolimus
- Where
- 5 sites in China
- Volunteers
- 61 people
- Sponsor
- Novartis Pharmaceuticals
Neuroendocrine Tumors, Prostate Cancer
Dual-Tracer Theranostic PET
This study is designed to obtain positron emission tomography with x-ray computed tomography (PET/CT) imaging data with each tracer pair, providing the imaging data needed to develop new simultaneous dual-tracer imaging…
- Trial name
- NCT05680675
- Testing
- Single-Tracer FDG PET/CT Exam, Single-Tracer Cu64-DOTATATE PET/CT Exam, Single-Tracer Ga68-DOTATATE PET/CT Exam
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- University of Utah
Carcinoid Tumor, Carcinoid Tumor of GI System
Cabozantinib and Nivolumab for Carcinoid Tumors
This research study, is studying the combination of cabozantinib and nivolumab in treating advanced carcinoid tumors. Carcinoid tumor is another term used to refer to neuroendocrine tumors that arise in organs such as the…
- Conditions
- Carcinoid Tumor, Carcinoid Tumor of GI System, Neuroendocrine Tumors
- Trial name
- NCT04197310
- Testing
- Nivolumab, Cabozantinib
- Where
- 2 sites in United States
- Volunteers
- 19 people
- Sponsor
- Dana-Farber Cancer Institute
Locally Advanced Digestive System Neuroendocrine Carcinoma, Locally Advanced Pancreatic Neuroendocrine Carcinoma
Liposomal Irinotecan, Fluorouracil and Leucovorin in Treating Patients With Refractory Advanced High Grade Neuroendocrine Cancer of Gastrointestinal, Unknown, or Pancreatic Origin
This phase II trial studies how well liposomal irinotecan, leucovorin, and fluorouracil work in treating patients with high grade neuroendocrine cancer of gastrointestinal, unknown, or pancreatic origin that does not respond to…
- Conditions
- Locally Advanced Digestive System Neuroendocrine Carcinoma, Locally Advanced Pancreatic Neuroendocrine Carcinoma, Metastatic Digestive System Neuroendocrine Carcinoma, Metastatic Pancreatic Neuroendocrine Carcinoma
- Trial name
- NCT03736720
- Testing
- Fluorouracil, Leucovorin, Liposomal Irinotecan
- Where
- 2 sites in United States
- Volunteers
- 11 people
- Sponsor
- Roswell Park Cancer Institute
Gastroenteropancreatic Neuroendocrine Tumors
Post-Authorization Safety Study (PASS) of LysaKare® in Adult Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET) Patients
The purpose of the study was to evaluate the effect of arginine/lysine solution administration on serum potassium levels. A systematic assessment of serum potassium levels was performed during infusion and up to 24 hours post…
- Trial name
- NCT04524442
- Testing
- arginine/lysine
- Where
- 7 sites in Italy, Netherlands and 2 more
- Volunteers
- 42 people
- Sponsor
- Advanced Accelerator Applications
Neuroendocrine Tumors, Neuroendocrine Neoplasm
Platinum-doublet Chemotherapy and Nivolumab for the Treatment of Subjects With Neuroendocrine Neoplasms (NENs) of the Gastroenteropancreatic (GEP) Tract or of Unknown (UK) Origin.
This is a prospective, multi-centre, open label, non-randomized phase II study evaluating the efficacy and safety of nivolumab plus platinum-based chemotherapy in patients with advanced G3 NENs of the GEP tract or of UK origin.
- Conditions
- Neuroendocrine Tumors, Neuroendocrine Neoplasm, Gastroenteropancreatic Neuroendocrine Tumor
- Trial name
- NCT03980925
- Testing
- Nivolumab, Carboplatin, Etoposide
- Where
- 12 sites in Spain
- Volunteers
- 37 people
- Sponsor
- Grupo Espanol de Tumores Neuroendocrinos
Neuroendocrine Tumors, Neuroendocrine Neoplasm of Lung
Durvalumab (MEDI4736) Plus Tremelimumab for Advanced Neuroendocrine Neoplasms of Gastroenteropancreatic or Lung Origin
Well-differentiated gastroenteropancreatic and lung neuroendocrine tumors are generally malignancies with a prolonged natural history.
- Trial name
- DUNE (NCT03095274)
- Testing
- Durvalumab, Tremelimumab
- Where
- 19 sites in Spain
- Volunteers
- 126 people
- Sponsor
- Grupo Espanol de Tumores Neuroendocrinos
Recurrent Neuroendocrine Tumor, Metastatic Neuroendocrine Tumor
Phase 2 Study of ONC201 in Neuroendocrine Tumors
The purpose of this study is to learn if a new drug, ONC201 can make tumors become smaller or go away completely. Investigators also want to learn if ONC201 can prevent new deposits of cancer from appearing in new places in…
- Trial name
- NCT03034200
- Testing
- ONC201
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Peter Anderson
Neuroendocrine Tumors
A Study of LEE011 With Everolimus in Patients With Advanced Neuroendocrine Tumors
The purpose of this study is to test any good and bad effects of the combination of LEE011 with everolimus on the participant and the cancer.
- Trial name
- NCT03070301
- Testing
- LEE011, everolimus
- Where
- 5 sites in United States
- Volunteers
- 21 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Cushing's Disease, Acromegaly
Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in Novartis-sponsored Studies
The purpose of this study is to allow continued use of pasireotide in patients who are on pasireotide treatment in a Novartis-sponsored study and are benefiting from the treatment as judged by the investigator.
- Conditions
- Cushing's Disease, Acromegaly, Neuroendocrine Tumors, Pituitary Tumors
- Trial name
- NCT01794793
- Testing
- Pasireotide, Cabergoline, Pasireotide LAR
- Where
- 94 sites in United States, Argentina and 26 more
- Volunteers
- 337 people
- Sponsor
- RECORDATI GROUP
Gastroenteropancreatic Neuroendocrine Tumor
Study to Assess the Efficacy and Safety of Lanreotide Autogel® in Chinese Participants With GEP-NETs
This study will be conducted to support the registration of the lanreotide Autogel 120 mg formulation in China for the treatment of GEP-NETs and treatment of clinical symptoms of NETs.
- Trial name
- PALACE (NCT04852679)
- Testing
- Lanreotide autogel
- Where
- 14 sites in China
- Volunteers
- 43 people
- Sponsor
- Ipsen
Neuroendocrine Tumors, Hepatic Metastases
Everolimus After (Chemo)Embolization for Liver Metastases From Digestive Endocrine Tumors
Determine wether 24 months treatment with everolimus prolongs progression free survival rate (based on a central assessment) after embolisation ou chemoembolisation for liver metastases.
- Conditions
- Neuroendocrine Tumors, Hepatic Metastases, Metastases
- Trial name
- EVACEL (NCT01678664)
- Testing
- Everolimus, embolization, Doxorubicin
- Where
- 18 sites in France
- Volunteers
- 74 people
- Sponsor
- Federation Francophone de Cancerologie Digestive
Carcinoid Syndrome
Real-world Evidence Study EvaLuating PAtient-Reported Outcomes With XERMELO
The primary objective of the study is to estimate the proportion of carcinoid syndrome (CS) patients who are satisfied with their overall symptom control, 6 months after initiating treatment with telotristat ethyl (XERMELO).
- Trial name
- RELAX (NCT03223428)
- Testing
- Xermelo
- Where
- United States
- Volunteers
- 223 people
- Sponsor
- TerSera Therapeutics LLC